Madrigal Pharmaceuticals, Inc. MDGL Business Segments — SG&A
Discontinued — last reported Q4 '25
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s business segments — sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s business segments — SG&A?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported business segments — SG&A of $239.98M in Q4 2025.
- How has Madrigal Pharmaceuticals, Inc.'s business segments — SG&A changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s business segments — SG&A increased by 69.9% year-over-year, from $141.22M to $239.98M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s business segments — SG&A?
- Over 2 years (2023 to 2025), Madrigal Pharmaceuticals, Inc.'s business segments — SG&A has grown at a 174.3% compound annual growth rate (CAGR), from $108.15M to $813.83M.
- What does business segments — SG&A mean?
- The total overhead and commercialization costs required to support the segment's business activities.
- How do you interpret business segments — SG&A?
- An increase often signals aggressive commercial expansion or market entry efforts, while a decrease may indicate cost-cutting measures or improved operational efficiency.
- How does business segments — SG&A compare across companies?
- Peers in the biopharmaceutical industry typically report this as SG&A, with levels varying significantly based on the stage of product commercialization.